www.risicare.ch

Personalized Medicine

in Switzerland

2 Swiss Academy of Medical Sciences / TA-SWISS

• ambitious concept

• modest response in politics and media so far

• sceptical voices prevail

• «Marketing instrument of the pharmaceutical

industry»

• «We will be the gravediggers of our own

private sphere»

• debate concentrates on special aspects

like genetic testing

Public perception

3 Swiss Academy of Medical Sciences / TA-SWISS

• strong privately financed research

• no explicit national programme

• multitude of individual projects

• need for complementing research

• legal aspects

• bioinformatics

• communication

• etc.

Research

4 Swiss Academy of Medical Sciences / TA-SWISS

• well established in centres of excellence

for example in university hospitals

• but: even specialists often overtaxed

• personalized medicine:

medicine for the person?

• the boundaries between

«healthy» and «ill» vanish

Medical practice

5 Swiss Academy of Medical Sciences / TA-SWISS

• strategy of the

federal administration

• central importance of standardised

electronic medical file

• federalist structure of health system

• niche for private services

• strong need for standardisation

E-Health

6 Swiss Academy of Medical Sciences / TA-SWISS

• collection of data

• types of data

• integration in electronic medical file

• open source vs. data protection

• new forms of research (crowd sourcing)

• data processing, data mining

• creating new assets

• area of conflict between

«private» und «public»

Internet and Social Media

7 Swiss Academy of Medical Sciences / TA-SWISS

• ban for direct to consumer genetic testing

• different regulations for the dealing with

genetic biomarkers and other biomarkers

• licensing of drugs tailor-made for blockbusters

• from informed consent to

«informed lack of knowledge»?

Legal challenges

8 Swiss Academy of Medical Sciences / TA-SWISS

• We are not yet well prepared

for a real breakthrough of personalized medicine

Present situation

9 Swiss Academy of Medical Sciences / TA-SWISS

• high potentials

• progress, especially in oncology

• limits of effectiveness

• importance for pharmaceutical industry

• need for action

• information and education

for physicians and patients

• label for physicians with special

competence

• improvements in medical genetics

and the use of case history

• evaluation of direct to customer

services

Position of the Swiss Academy of Medical Sciences

10 Swiss Academy of Medical Sciences / TA-SWISS

• strong pharmaceutical and medtech industry

in Switzerland

• need for innovative concepts

• alternative to the blockbuster-model

- with chances and risks

• interest in limiting costs for clinical studies

• new services for new customers

• consequences for political economy

open

Economic aspects

11 Swiss Academy of Medical Sciences / TA-SWISS

• obligatory health insurance:

principle of solidarity between the healthy and the ill, younger

and older people, men and women well established

• solidarity in society:

important role of personal responsibility / personal autonomy

decreasing patience with those, who do not care for their

health?

• balance between individual capacities

and individual needs

Concept of solidarity

12 Swiss Academy of Medical Sciences / TA-SWISS

• technology assessment

as a catalyst

• intensifying the political

and societal debate

Outlook

13 Swiss Academy of Medical Sciences / TA-SWISS

Thank you

for your attention